drugset
drugset / Trial / NCT04053803

An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia

NCT04053803 ↗

Phase 2 Active not recruiting 30 enrolled Imara, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label extension study of IMR-687 in adult patients who completed Imara's blinded Phase 2a study (IMR-SCD-102). The open-label extension study will evaluate long-term safety and tolerability.

Timeline

Start
2019-05-22
Primary completion
2025-03
Completion
2025-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Tovinontrine Small molecule — Oral

Indications

sickle cell disease